{'fraction_non_alphanumeric': 0.01984126984126984, 'fraction_numerical': 0.007936507936507936, 'mean_word_length': 6.074766355140187, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of growth hormone replacement therapy on adrenal androgen secretion in adult onset hypopituitarism

objective Growth hormone replacement therapy in GH‐deficient children is associated with enhanced adrenal androgen production, raising the possibility that GH might stimulate adrenocortical hormone secretion. This has not been extensively investigated in adults to date. GH is a potent modulator of the activity of the 11β‐hydroxysteroid dehydrogenase type 1 (11β‐HSD1) enzyme and by altering cortisol metabolism can affect the function of the hypothalamo–pituitary–adrenal (HPA) axis and therefore potentially of adrenal androgen secretion. This study examined the effects of GH replacement in GH‐deficient adults on adrenal androgen secretion.